Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Director/PDMR Shareholding

4 Oct 2010 09:45

RNS Number : 7863T
Allergy Therapeutics PLC
04 October 2010
 



Allergy Therapeutics PLC

4 October 2010

 



Monday 4 October 2010

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Major Shareholdings/Holding by Director

 

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specializing in allergy vaccines announces today that 137,491,788 of its ordinary shares were transferred on 28 September 2010 by Azure Ventures Limited to Yissum Holdings Limited a company controlled by members of the Weinstein family, including Mr Alejandro Weinstein Jr, a non-executive director of the Company. Notification of the transfer was received by the Company on 4 October 2010. There has been no change in the aggregate beneficial holding of shares in the Company by the Weinstein family.

 

 

The Karjiang Pharma Trust, of which the Weinstein family, including Mr Alejandro Weinstein Jr., are beneficiaries, continues to hold 3,076,499 shares in the Company, through Azure Ventures Limited. As a result of the transfer the percentage of voting rights controlled by the Karjiang Pharma Trust has fallen from 45.23 per cent. to below 3 per cent.

 

Yissum Holdings Limited, a company which is controlled by the Weinstein family, including Mr Alejandro Weinstein Jr., now holds 137,491,788 shares in the Company, representing 44.24 per cent. of the Company's total voting rights.

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Christopher Golden

www.nomuracode.com

 

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGIBDGXSGBGGS
Date   Source Headline
31st Mar 20267:00 amRNSInterim Results for six months ended 31 Dec 2025
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
4th Mar 20267:00 amRNSPositive Biomarker Results from PROTECT Trial
26th Feb 20267:00 amRNS-RAllergy Therapeutics presents progress at AAAAI
23rd Feb 20267:51 amRNSUpdate on funding and total voting rights
30th Jan 20268:22 amRNSChief Strategy Officer and Board appointments
29th Jan 20262:13 pmRNSResult of Annual General Meeting
28th Jan 20264:48 pmRNSGrant of Options under Long Term Incentive Scheme
19th Jan 20267:00 amRNSHalf Year Trading Update
6th Jan 20267:00 amRNSNotice of 2025 Annual General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
16th Dec 20257:00 amRNSGrassmuno® marketing authorisation in Germany
12th Dec 20257:00 amRNSAuthority for allotment of New Shares
11th Dec 20257:00 amRNSPrelim Results and publication of Annual Report
9th Dec 20257:00 amRNSPrimary Safety Endpoint Met in PROTECT trial
6th Nov 20257:22 amRNSCompany to Evaluate Dual Listing on HKEX
30th Oct 20257:00 amRNSG308 Phase III Year 2 Patient Screening Starts
29th Oct 20257:00 amRNSWarrant Exercise and Paydown of Debt
16th Oct 20257:00 amRNSFurther progress in Phase I/IIa PROTECT trial
31st Jul 20257:00 amRNS-RGrass MATA MPL Publications in Allergy Journal
21st Jul 20257:00 amRNSTrading update for the year ended 30 June 2025
11th Jul 20257:00 amRNSPDMR Dealings
13th Jun 20257:00 amRNS-RAllergy Therapeutics presents findings at EAACI
10th Jun 20257:04 amRNS-REAACI Early Career Research Award
31st Mar 20257:00 amRNSInterim Results for six months ended 31 Dec 2024
27th Mar 20257:00 amRNSAdvancement to final phase of PROTECT trial
3rd Mar 20257:00 amRNSNew Executive Long Term Incentive Awards
27th Feb 20257:00 amRNS-RPresentations at 2025 AAAAI / WAO Joint Congress
17th Feb 20257:00 amRNSGrass MATA MPL Phase III data published in Allergy
14th Feb 20257:00 amRNSGrant of Options
28th Jan 20257:00 amRNSHalf Year Trading update
22nd Jan 20257:00 amRNSPDMR Dealing and Total Voting Rights
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20241:41 pmRNSExercise of Options and Total Voting Rights
17th Dec 20244:19 pmRNSBlock Listing Interim Review
16th Dec 20243:33 pmRNSResult of Annual General Meeting
4th Dec 20247:00 amRNSPositive Interim Data from PROTECT Trial
27th Nov 20247:00 amRNSFirst Patient Dosed in G308 Paediatric Trial
25th Nov 20247:00 amRNSSubmission of MAA for Grass MATA MPL
21st Nov 20247:00 amRNSNotice of 2024 Annual General Meeting
6th Nov 20247:00 amRNSAudited Preliminary Results 2024
21st Oct 20247:00 amRNSCommencement of Phase III Paediatric Trial
16th Oct 20247:00 amRNSUpdate on funding
1st Oct 20247:00 amRNSUpdate on funding and preliminary results
17th Sep 20247:00 amRNSProgression of patient cohorts in PROTECT Trial
27th Aug 20247:00 amRNSUpdate on funding
22nd Jul 20247:01 amRNSTrading update for the year ended 30 June 2024
22nd Jul 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.